Topics:

AIDS Dementia: Current Status and New Treatment Approaches

AIDS Dementia: Current Status and New Treatment Approaches

In the long list of morbidities associated with HIV-1 infection, the most common neurodegenerative disorder is HIV-associated dementia (HAD).1 Symptoms are classic signs of cognitive impairment: confusion, forgetfulness, slowed thinking, and poor concentration. Behavioral changes include dysphoria, reduced emotional responsiveness, social withdrawal, and apathy. Psychiatric symptoms resembling those seen in severe psychiatric disorders—severe agitation, delusions, and hallucinations—also emerge in some affected persons. In the later and final stages of HAD, patients often exhibit a vastly diminished reaction to their environment accompanied by neurological deficits that include balance difficulties, leg weakness, and reduced dexterity.2

"We believe that some degree of cognitive impairment is common in people infected with HIV," said Howard Crystal, MD, professor of neurology and pathology at SUNY Downstate Medical College in Brooklyn, New York. "We do not yet know all the factors that contribute to this cognitive impairment, but some of these factors include gender, the severity of the HIV infection, and the nature of the antiretroviral therapy. In evaluating these factors, we must take into account host genetics, viral genetics, premorbid mental ability, substance abuse, psychiatric disorders, and inflammatory markers."

EARLY CNS INVOLVEMENT

As AIDS-associated cognitive impairment became better understood, it became apparent that HAD was not merely the sequela of an opportunistic infection but was the effect of HIV-1 viremia. Accumulated clinical data also revealed CNS involvement even before the development of the usual opportunistic infections and frank AIDS.3 Data from the CDC suggested that CNS complications made up approximately 8% of AIDS-defining diseases,4 whereas an earlier survey involving cohorts from large urban centers concluded that 39% of patients with AIDS or HAD suffered from neurological symptoms and that approximately 10% of patients with AIDS had complaints directly attributable to CNS involvement.5

"Data already collected on the prevalence of cognitive impairment due to HIV infection ranges from none to as high as 50% or 60%, depending on the cohort and the way the study was conducted," Crystal remarked. "How a clinician should treat cognitive impairment when HIV is present is controversial, and no one clear guideline is available."

Most experts in HIV dementia recommend that patients undergo diagnostic imaging, according to Crystal. "If the images are consistent with HIV dementia, then a lumbar puncture should be performed to look for opportunistic infections. This is not terribly controversial. The real issue here is to what extent the HIV virus is in the brain and in the spinal fluid and how that differs with regard to the viremia load. There is no clear-cut answer to this question. Most experts would tell you to use antiretrovirals that get into the brain. However, the direct efficacy of this approach has yet to be proved," Crystal said.

Brain tissue is particularly susceptible to damage caused by immune reactions and infectious disease. The most critical protective structure in the CNS is the blood-brain barrier (BBB). Viruses pass through the BBB by hitching a ride on surveillance macrophages along with lymphocytes and monocytes. This hematogenous route of invasion has been termed the "Trojan horse model of infection of the CNS," and it is believed to be the main mechanism involved in the inva- sion of nervous tissue by HIV-1.6

Psychometric testing of patients with HAD is important. However, the disorder is not readily assayed using the Mini-Mental State Examination unless the patient has frank dementia. If HAD is suspected in a seroconverted patient, the HIV Dementia Scale, the Mental Alteration Test, the Executive Interview, and the HIV Dementia Assessment are useful in establishing a definitive diagnosis. The Memorial Sloan-Kettering Scale, a psychometric tool structured to give a qualitative evaluation of dementia severity, helps in clinical staging by allowing the clinician to follow the progression of HAD.6

CLINICAL PRESENTATION

"HAD usually appears when the CD4+ cell count is less than 200/µL, and that is about 7 to 9 years after initial HIV infection and seroconversion," explained Crystal. "The HIV virus does not attack neurons; it attacks the microglial cells, which are the brain's equivalent of the macrophages or the scavenger cells. However, the presence of the HIV virus does make neurons get sick and die. Many areas of the brain are affected, including the basal ganglia, white matter, and perhaps some brain stem regions, but clearly the neocortex is involved to the extent that if you did a cell count, you would see a 50% decrease in neurons compared with controls. In addition, in the neocortex and the hippocampus, you would see about 90% overall neuron destruction compared with controls."

This neuronal death is referred to as cortical dementia, according to Crystal. Language is relatively well preserved; however, patients often complain of loss of concentration, slowness of thoughts, and forgetfulness.7 In addition to cognitive deficits, approximately 75% of patients demonstrate unsteady gait, about 50% report clumsiness and deteriorating handwriting, and approximately 30% complain of tremor.8

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.